Articles By Jack Cush, MD
Birthday Gatherings Increase COVID-19 Risk
By Jack Cush, MD
24 June 2021
How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population.
Read Article
Knee Replacement in Obese OA is Cost Effective
By Jack Cush, MD
24 June 2021
Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m2) with
Read Article
Better Outcomes with Modern T2T in Pregnancy
By Jack Cush, MD
23 June 2021
With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.
Read Article
Progression from Psoriasis to Psoriatic Arthritis
By Jack Cush, MD
22 June 2021
The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).
Read Article
FINCH 1 Trial Filgotinib in Rheumatoid Arthritis
By Jack Cush, MD
22 June 2021
The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).
Read Article
Treatment of MIS-C COVID in Kids
By Jack Cush, MD
21 June 2021
The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular complic
Read Article
Tofacitinib Efficacy in COVID-19 Pneumonia
By Jack Cush, MD
21 June 2021
NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.
Read Article
RheumNow Podcast - Speak Up! (6.18.2021)
By Jack Cush, MD
18 June 2021
Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!
Read Article
EULAR 2021 – Day 4 Report
By Jack Cush, MD
17 June 2021
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Read Article
Problems at the FDA
By Jack Cush, MD
16 June 2021
"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee convened by
Read Article